Oskar Hansson
151 – 200 of 544
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
(
- Contribution to journal › Article
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article
-
Mark
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
(
- Contribution to journal › Article
-
Mark
Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
(
- Contribution to journal › Article
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Time between milestone events in the Alzheimer's disease amyloid cascade
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study
(
- Contribution to journal › Article
-
Mark
Biomarkers for neurodegenerative diseases
(
- Contribution to journal › Scientific review
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
(
- Contribution to journal › Article
-
Mark
Sex differences in off-target binding using tau positron emission tomography
(
- Contribution to journal › Article
-
Mark
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
(
- Contribution to journal › Article
-
Mark
Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
(
- Contribution to journal › Article
-
Mark
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
Neuroligin-1 in brain and CSF of neurodegenerative disorders : investigation for synaptic biomarkers
(
- Contribution to journal › Article
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers : methodological update
(
- Contribution to journal › Article
-
Mark
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Management of Alzheimer's disease takes a leap forward
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
(
- Contribution to journal › Article
-
Mark
A multicentre validation study of the diagnostic value of plasma neurofilament light
(
- Contribution to journal › Article
-
Mark
Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment
(
- Contribution to journal › Article
-
Mark
Genetic interaction study of Alzheimer's disease quantitative biomarkers : A polygenic risk score analysis and evaluation
(
- Contribution to journal › Article
-
Mark
CSF Aβ42 and Aβ40 and their relation to brain soluble and insoluble Aβ in the 5xFAD mouse model of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Mapping genetic determinants of 184 circulating proteins in 26,494 individuals to connect proteins and diseases
2021)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19
2021)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease : A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
(
- Contribution to journal › Article
-
Mark
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study
(
- Contribution to journal › Article